3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
13
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Solid Tumors Harboring a BRAF V600 Mutation
1
Skin Neoplasms
1
Skin Diseases
1
Pancreatic Neoplasms
1
Lymphatic Metastasis
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Astrocytoma
1
Advanced BRAF Mutant Cancers
1
Interventions
Cyclophosphamide
34
fludarabine
25
fludarabine phosphate
24
Tacrolimus
24
Mycophenolic Acid
23
Whole-Body Irradiation
22
Busulfan
15
Methotrexate
12
Melphalan
12
Granulocyte Colony-Stimulating Factor
12
Antilymphocyte Serum
12
thymoglobulin
11
Cyclosporine
11
Stem Cell Transplantation
10
Filgrastim
10
Rituximab
9
Thiotepa
7
Peripheral Blood Stem Cell Transplantation
7
Nivolumab
7
Dexamethasone
7
trametinib
6
Radiotherapy
6
Mesna
6
Cytarabine
6
Prednisone
5
Calcium Dobesilate
5
Bortezomib
5
Azacitidine
5
Alemtuzumab
5
Voriconazole
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hematologic Neoplasms
×
encorafenib
×
Clear all
NCT01981187
2021-03-26
SIGNATURE
Pfizer
Phase 2
Terminated
12 enrolled
13 charts